NanoBone Bone Grafts by Biocomposites Now Available for UK Surgeons

Biocomposites, a leader in medical device innovation, is launching the distribution of its NanoBone product range in the UK. The range, including NanoBone SBX Putty and NanoBone QD, offers next-generation synthetic bone grafts designed to accelerate early osteogenesis and bone formation. Featuring a unique composition of nanostructured hydroxyapatite within a silica gel matrix, NanoBone provides a healing rate comparable to autografts, minus the complications of graft harvesting.

This ready-to-use product simplifies surgery, delivering flexibility and efficiency to surgeons. The launch in the UK marks a significant expansion for Biocomposites, which already serves over 100,000 patients worldwide. The products will be unveiled at the British Orthopaedic Association's Annual Congress in Birmingham.

Biocomposites' acquisition of Artoss, a German bone graft substitute manufacturer, has enabled the NanoBone range to reach more than 40 countries. This solidifies Biocomposites’ position as a leader in bone regeneration and infection management.